0.87

38.90% -0.56

Verrica Pharmaceuticals Inc (VRCA)

Overview News Price History Option Chain Financials Discussions Forecast

Verrica Pharmaceuticals Inc stock is traded at $0.87, with a volume of 2.54M. It is down -38.90% in the last 24 hours and down -33.31% over the past month. Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Previous Close:

$1.43

Open:

$0.93

24h Volume:

2.54M

Relative Volume:

2.55

Market Cap:

$61.02M

Revenue:

$5.12M

Net Income/Loss:

$-67.00M

P/E Ratio:

-1.6474

EPS:

-0.5281

Net Cash Flow:

$-38.94M

1W Performance:

-47.99%

1M Performance:

-33.31%

6M Performance:

-87.97%

1Y Performance:

-78.16%

1-Day Range:

$0.7472

$0.9389

1-Week Range:

$0.7472

$1.7382

52-Week Range:

$0.7472

$11.41

Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile

Name

Verrica Pharmaceuticals Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

484-453-3300

Address

10 NORTH HIGH STREET, WEST CHESTER, PA

Employee

100

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

VRCA's Discussions on Twitter

Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-25-23	Upgrade	Needham	Hold → Buy
Mar-22-23	Initiated	Jefferies	Buy
Feb-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
May-25-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
May-14-21	Initiated	RBC Capital Mkts	Outperform
Dec-24-20	Reiterated	H.C. Wainwright	Buy
Jul-15-20	Downgrade	BofA Securities	Buy → Neutral
Jun-30-20	Reiterated	H.C. Wainwright	Buy
Jun-24-20	Initiated	Northland Capital	Outperform
Mar-24-20	Initiated	Needham	Buy
Feb-21-19	Initiated	H.C. Wainwright	Buy

View All

Verrica Pharmaceuticals Inc Stock (VRCA) Latest News

12:22 PM

U.S. Stock market: Bluejay Diagnostics (+105.33%), Zoomcar Holdings (+180.40%), and Verrica Pharmaceuticals(+39.10%) among the most volatile stocks during mid day trading - Business Upturn

12:22 PM

10:00 AM

U.S. Stock market: Verrica Pharmaceuticals and Marqeta stocks plummet over 37%, while Avalon GloboCare soars 75% in volatile market trend - Business Upturn

10:00 AM

09:40 AM

Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat

09:40 AM

09:32 AM

Verrica Pharmaceuticals stock hits 52-week low at $0.93 By Investing.com - Investing.com UK

09:32 AM

07:13 AM

Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded by Royal Bank of Canada to "Sector Perform" - MarketBeat

07:13 AM

01:05 AM

Verrica Pharmaceuticals Appoints Jayson Rieger as New CEO - Marketscreener.com

01:05 AM

Nov 04, 2024

Verrica Pharmaceuticals earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada

Nov 04, 2024

Shares of Verrica Pharmaceuticals Tumble Following 3Q Results, Operational Changes - MarketWatch

Nov 04, 2024

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition - GlobeNewswire

Nov 04, 2024

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership - The Bakersfield Californian

Nov 04, 2024

Oct 30, 2024

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update - Defense World

Oct 30, 2024

Oct 28, 2024

Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Expands By 24.8% - MarketBeat

Oct 28, 2024

Oct 24, 2024

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference - GlobeNewswire

Oct 24, 2024

Oct 22, 2024

Pharma Co. Verrica Faces Derivative Suit Over FDA Inspection - Law360

Oct 22, 2024

Oct 21, 2024

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Oct 21, 2024

Verrica Pharmaceuticals (NASDAQ:VRCA) Given New $10.00 Price Target at TD Cowen - MarketBeat

Oct 21, 2024

Verrica shares price target cut by TD Cowen - Investing.com Canada

Oct 21, 2024

Oct 11, 2024

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc.VRCA - Business Wire

Oct 11, 2024

Oct 10, 2024

GLP-1 Receptor Agonist Market Set to Witness Significant Growth by 2024-2031:Verrica Pharmaceuticals, AbbVie - EIN News

Oct 10, 2024

Oct 09, 2024